A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment
Ovarian Cancer
DRUG: ZL-2306 (Nirapairb)|DRUG: Placebo Comparator
BICR-assessed progression-free survival (PFS), the time from randomization to progressive disease or death due to various causes assessed by the BICR according to RECIST 1.1, whichever occurs first, Approximately 36 months since the first subject enrolled
Overall survival (OS), the time from the date of randomization to the date of death caused by any reason., Approximately 36 months since the first subject enrolled|Time to first subsequent anti-tumor treatment (TFST), the time from the date of randomization in the study to the date when the first subsequent anti-tumor treatment starts, Approximately 36 months since the first subject enrolled|PFS and OS assessed by BICR in patients with HRD (homologous recombination defects), positive patient population (including gBRCA-positive patients)., Approximately 36 months since the first subject enrolled
Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment